USPTO serial 79351011
KALVISTA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 29, 2023
- Examiner
- JOINER, KATINA JACKSON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KALVISTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacy L. Wu
Stacy L. Wu Cast Legal Studio PLLC4 International Drive, Suite 110Rye Brook, NY 10573United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders | ACTIVE | — |
| 010 | Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders | ACTIVE | — |
| 042 | Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders | ACTIVE | — |
| 044 | Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kalvista Pharmaceuticals Limited
- Other trademarks owned by Kalvista Pharmaceuticals Limited
- Other trademarks owned by Kalvista Pharmaceuticals Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KALVISTA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 20, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 9, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 9, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 9, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 9, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 9, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 23, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 29, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 29, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 28, 2023 | GPAR | GRANT OF PROTECTION CREATED, TO BE SENT TO IB | — |
| Aug 29, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 13, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 24, 2023 | NPUB | NOTICE OF PUBLICATION | — |
| May 6, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 5, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 4, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 30, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 29, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |